{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"description":"OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG000","title":"Thalidomide + Prednisolone [TP Consolidation]"},{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m\\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG001","title":"Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]"}],"paramType":"MEDIAN","populationDescription":"All randomized analysis set was defined as participants in the all enrolled set (all participants with a non-missing informed consent date and were not screen failures) who were randomized to receive consolidation treatment.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}